HYDERABAD, Dec 26: Leading generic drug maker Dr Reddys Laboratories Ltd (DRL) today said its shipments meant for Canada pose no risk to the health and safety of the Canadian people and its decision to place under quarantine formulations meant for that country is “voluntary”.
“In keeping with current regulations of Health Canada, the company has voluntarily placed under quarantine all APIs (active pharmaceutical ingredients) and the formulations based on APIs produced at our API facility in Srikakulam district of Andhra Pradesh intended for use in Canada,” the company said in a statement.
DRL said its products continue to meet intended quality standards, and “we believe that, our APIs and finished drug products manufactured using these APIs pose no risk to the health and safety of the Canadian people”.
The company is working with the agency for a satisfactory resolution of the matter, it said. “At this stage, it has no implication on any activity at the plant and hence, these are not expected to be material to the Company’s operations or consolidated results,”DRL said.
(UNI)
Trending Now
E-Paper
Follow our WhatsApp channel